Dual-action therapies are rapidly evolving as a groundbreaking approach in the fight against both HIV and cancer. These treatments attack several pathways within cancer cells, offering {a{ promise of improved efficacy and reduced side effects compared to traditional single-target approaches. By leveraging different therapeutic modalities, dual-acti